SANOFI AVENTIS US Company Profile

What is the competitive landscape for SANOFI AVENTIS US

SANOFI AVENTIS US has one hundred and twenty approved drugs.

There are ten US patents protecting SANOFI AVENTIS US drugs.

There are two hundred and eighteen patent family members on SANOFI AVENTIS US drugs in fifty-three countries and one hundred and eleven supplementary protection certificates in nineteen countries.

Summary for SANOFI AVENTIS US

International Patents:	218
US Patents:	10
Tradenames:	95
Ingredients:	84
NDAs:	120

Drugs and US Patents for SANOFI AVENTIS US

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AUBAGIO	teriflunomide	TABLET;ORAL	202992-001	Sep 12, 2012	AB	RX	Yes	No	8,802,735*PED				Y
Sanofi Aventis Us	BRICANYL	terbutaline sulfate	TABLET;ORAL	017618-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	BRICANYL	terbutaline sulfate	INJECTABLE;INJECTION	017466-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sanofi Aventis Us	GLYBURIDE (MICRONIZED)	glyburide	TABLET;ORAL	020055-002	Apr 17, 1992		DISCN	No	No
Sanofi Aventis Us	JEVTANA KIT	cabazitaxel	SOLUTION;INTRAVENOUS	201023-001	Jun 17, 2010	AP	RX	Yes	Yes	8,927,592*PED				Y
Sanofi Aventis Us	PRIFTIN	rifapentine	TABLET;ORAL	021024-001	Jun 22, 1998		RX	Yes	Yes
Sanofi Aventis Us	PRIMACOR IN DEXTROSE 5% IN PLASTIC CONTAINER	milrinone lactate	INJECTABLE;INJECTION	020343-002	Aug 9, 1994		DISCN	Yes	No

Expired US Patents for SANOFI AVENTIS US

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	AMARYL	glimepiride	TABLET;ORAL	020496-001	Nov 30, 1995	4,379,785*PED
Sanofi Aventis Us	DIABETA	glyburide	TABLET;ORAL	017532-002	May 1, 1984	3,454,635
Sanofi Aventis Us	LOVENOX (PRESERVATIVE FREE)	enoxaparin sodium	INJECTABLE;SUBCUTANEOUS	020164-007	Jun 2, 2000	5,389,618
Sanofi Aventis Us	ORNIDYL	eflornithine hydrochloride	INJECTABLE;INJECTION	019879-002	Nov 28, 1990	4,399,151
Sanofi Aventis Us	PERTOFRANE	desipramine hydrochloride	CAPSULE;ORAL	013621-002	Approved Prior to Jan 1, 1982	3,454,698
Sanofi Aventis Us	PLAVIX	clopidogrel bisulfate	TABLET;ORAL	020839-001	Nov 17, 1997	5,576,328*PED
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996	5,714,512*PED

Paragraph IV (Patent) Challenges for SANOFI AVENTIS US drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Injection	40 mg/mL, 0.5 mL and 2 mL vials		2009-06-30
	For Injection	50 mg/vial and 100 mg/vial		2007-02-09
	Injection	5 mg/mL, 40 mL vial		2011-03-23
	Tablets	7 mg and 14 mg		2016-09-12
	Tablets	300 mg/25 mg		2006-06-06
	Tablets	400 mg		2013-07-01
	Injection	5 mg/mL, 10 mL and 20 mL vials		2007-02-09
	Injection	200 mg/40 mL		2007-07-16
	Injection	100 mg/mL, 3 mL vials		2006-12-07
	Tablets	150 mg/12.5 mg and 300 mg/12.5 mg		2004-11-10
	Tablets	75 mg, 150 mg and 300 mg		2004-05-25
	Tablets	300 mg		2009-03-04

International Patents for SANOFI AVENTIS US Drugs

Country	Patent Number	Estimated Expiration
Austria	396719
China	102065857
European Patent Office	2280701
Japan	2011518147
Mexico	2010011414
Nicaragua	201000172
Russian Federation	2342373

Supplementary Protection Certificates for SANOFI AVENTIS US Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0680967	01C0055	France		PRODUCT NAME: TELITHROMYCINE; REGISTRATION NO/DATE: EU/1/01/191/001 20010709
1667986	122013000050	Germany		PRODUCT NAME: ACETON-SOLVAT VON CABAZITAXEL; REGISTRATION NO/DATE: EU/1/11/676/001 20110317
1381356	132014902231965	Italy		AUTHORISATION NUMBER(S) AND DATE(S): EU/1/13/838, 20130826;EU/1/13/838, 20130826
0302769	98C0036	Belgium		PRODUCT NAME: CLOPIDOGREL HYDROGENE SULFATE; REGISTRATION NO/DATE IN FRANCE: EU/1/98 /069/001 DU 19980715; REGISTRATION NO/DATE AT EEC: DU EU/1-/98/069/001
0454511	C980039	Netherlands		PRODUCT NAME: IRBESARTAN, DESGEWENST IN DE VORM VAN EEN ZOUT EN/OF EEN HYDRAA T; REGISTRATION NO/DATE: EU/1/97/046/001 - 009 19970827
1381356	SPC/GB14/011	United Kingdom		PRODUCT NAME: TERIFLUNOMIDE, ITS STEREOISOMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/13/838/001-005 20130829
3300601	SPC/GB22/029	United Kingdom		PRODUCT NAME: COMBINATION OF DAUNORUBICIN AND CYTARABINE; REGISTERED: UK EU/1/18/1308(FOR NI) 20180827; UK FURTHER MA ON IPSUM 20180827

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Sanochemia Corp Usa
• Sanofi
• Sanofi Aventis Us

Pharmaceutical Competitive Landscape Analysis: Sanofi Aventis US – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, Sanofi Aventis US stands as a formidable player, navigating the complex landscape with strategic prowess and innovative solutions. As we delve into the competitive landscape of this pharmaceutical giant, we'll uncover its market position, strengths, and strategic insights that shape its trajectory in the US market.

Sanofi's Market Position in the US

Sanofi Aventis US, a subsidiary of the global pharmaceutical company Sanofi, has established a strong foothold in the American healthcare sector. With a diverse portfolio spanning multiple therapeutic areas, Sanofi has positioned itself as a key player in the US pharmaceutical market.

Revenue and Market Share

In 2024, Sanofi's US sales reached an impressive €4,751 million, marking a substantial 19.8% increase[1]. This growth underscores the company's robust performance and expanding market presence in the United States.

Key Therapeutic Areas

Sanofi's success in the US market is largely attributed to its focus on critical therapeutic areas:

1. Immunology
2. Vaccines
3. Rare Diseases
4. Oncology
5. Neurology

Sanofi's Competitive Strengths

Innovative Product Portfolio

At the heart of Sanofi's competitive edge lies its innovative product portfolio. The company's commitment to breakthrough science has resulted in the development of game-changing medications that address unmet medical needs.

Dupixent: A Blockbuster Success

"Dupixent sales were €3,303 million, the first quarter above the €3 billion level, and increased by 29.2%. In the US, sales were €2,407 million and increased by 23.8%."[1]

Dupixent, Sanofi's flagship product, has emerged as a true blockbuster in the US market. Its success in treating various inflammatory conditions has significantly contributed to the company's growth and market position.

Strong R&D Capabilities

Sanofi's robust research and development pipeline is a cornerstone of its competitive strategy. The company's focus on six potentially transformative medicines demonstrates its commitment to innovation and long-term growth[3].

Strategic Partnerships and Acquisitions

Sanofi has strategically leveraged partnerships and acquisitions to enhance its market position and expand its capabilities. These collaborations have allowed the company to access new technologies, markets, and resources, accelerating innovation and expanding its global footprint[4].

Market Challenges and Opportunities

Patent Expirations and Generic Competition

Like many pharmaceutical companies, Sanofi faces the challenge of patent expirations for some of its key drugs. This opens the door for generic competitors, potentially impacting sales and market share[10].

Regulatory Landscape

The heavily regulated pharmaceutical industry presents both challenges and opportunities for Sanofi. Navigating the complex regulatory environment requires agility and strategic foresight to ensure compliance while maintaining innovation[10].

Emerging Market Opportunities

Sanofi's strong presence in emerging markets presents significant growth opportunities. As healthcare needs evolve in these regions, Sanofi is well-positioned to capitalize on new market demands[8].

Strategic Insights and Future Outlook

Focus on Immunology Leadership

Sanofi aims to become a leading company in immunology, targeting millions of patients suffering from dermatological, respiratory, gastroenterological, and other immune-mediated diseases[2].

Vaccine Innovation

With a strong foundation in vaccine development, Sanofi is poised to leverage its expertise in addressing global health challenges. The company's commitment to vaccine innovation positions it as a key player in preventative healthcare[2].

Digital Transformation and Personalized Medicine

Embracing digital technologies and advancing personalized medicine approaches are key strategic priorities for Sanofi. These initiatives aim to enhance patient outcomes and streamline healthcare delivery[4].

Competitive Landscape Analysis

Key Competitors

Sanofi faces stiff competition from other pharmaceutical giants in the US market, including:

1. Pfizer
2. Johnson & Johnson
3. AbbVie
4. Merck & Co.
5. Novartis

Comparative Analysis

When compared to its competitors, Sanofi's diverse portfolio and strong presence in key therapeutic areas provide a competitive advantage. However, the company must continue to innovate and adapt to maintain its market position[9].

Financial Performance and Market Outlook

Recent Financial Results

Sanofi's strong financial performance in recent quarters reflects its successful strategy execution. The company's focus on key growth drivers, particularly Dupixent and vaccines, has yielded positive results[1].

Future Growth Projections

"The U.S. pharmaceutical market size was valued at USD 602.19 billion in 2023 and is projected to surpass around USD 1093.79 billion by 2033, registering a CAGR of 6.15% from 2024 to 2033."[5]

With the US pharmaceutical market projected to grow significantly over the next decade, Sanofi is well-positioned to capitalize on this expansion through its innovative product pipeline and strategic initiatives.

Strategic Initiatives for Market Dominance

R&D Investment

Sanofi has announced plans to increase its R&D investments to fully realize its pipeline potential and drive long-term growth[7]. This commitment to innovation is crucial for maintaining a competitive edge in the rapidly evolving pharmaceutical landscape.

Consumer Healthcare Separation

In a strategic move to enhance focus and resource allocation, Sanofi has announced its intention to separate its Consumer Healthcare Business. This decision aims to allow greater management focus on the core Biopharma business[7].

Digital Health Integration

Embracing digital health technologies and data analytics is a key strategic priority for Sanofi. By leveraging these tools, the company aims to enhance drug discovery, improve clinical trial efficiency, and deliver personalized healthcare solutions.

Challenges and Risk Factors

Market Volatility

The pharmaceutical industry is subject to market volatility influenced by factors such as regulatory changes, economic fluctuations, and global health crises. Sanofi must navigate these uncertainties to maintain its market position.

Pricing Pressures

Increasing scrutiny on drug pricing in the US market poses a challenge for pharmaceutical companies, including Sanofi. Balancing innovation costs with pricing strategies will be crucial for sustained growth.

Sanofi's Competitive Advantages

Global Reach and Local Expertise

Sanofi's extensive global presence, combined with its deep understanding of local markets, provides a significant competitive advantage. This allows the company to tailor its strategies to specific regional needs while leveraging its global resources.

Diverse Product Portfolio

The company's diverse product portfolio across multiple therapeutic areas helps mitigate risks associated with market fluctuations in any single domain. This diversification strategy contributes to Sanofi's resilience in the competitive landscape.

Future Trends and Opportunities

Personalized Medicine

As the healthcare industry moves towards more personalized treatment approaches, Sanofi's investments in genomics and targeted therapies position it well to capitalize on this trend.

Emerging Therapeutic Areas

Identifying and investing in emerging therapeutic areas, such as gene therapy and regenerative medicine, presents significant growth opportunities for Sanofi in the US market.

Key Takeaways

• Sanofi Aventis US has demonstrated strong growth in the US market, with sales reaching €4,751 million in 2024, a 19.8% increase.
• Dupixent stands out as a blockbuster product, driving significant revenue growth for the company.
• Strategic focus on immunology leadership and vaccine innovation positions Sanofi for future success.
• Increased R&D investments and the planned separation of the Consumer Healthcare Business reflect Sanofi's commitment to long-term growth and shareholder value.
• Navigating challenges such as patent expirations and regulatory pressures will be crucial for maintaining market dominance.
• Embracing digital health technologies and personalized medicine approaches presents significant opportunities for future growth.

FAQs

1. What is Sanofi's main competitive advantage in the US pharmaceutical market? Sanofi's main competitive advantage lies in its diverse product portfolio, strong R&D capabilities, and focus on key therapeutic areas such as immunology and vaccines.

2. How is Sanofi addressing the challenge of patent expirations? Sanofi is addressing patent expirations by investing heavily in R&D to develop new, innovative drugs and by strategically diversifying its product portfolio to reduce reliance on any single product.

3. What role does Dupixent play in Sanofi's US market strategy? Dupixent is a key growth driver for Sanofi in the US market, with sales exceeding €3 billion in a single quarter and showing strong year-over-year growth.

4. How is Sanofi positioning itself in the emerging field of personalized medicine? Sanofi is investing in genomics, targeted therapies, and digital health technologies to advance personalized medicine approaches and enhance patient outcomes.

5. What are the potential impacts of Sanofi's planned separation of its Consumer Healthcare Business? The separation is expected to allow greater management focus and resource allocation to the core Biopharma business, potentially driving innovation and growth in key therapeutic areas.

Sources cited: [1] https://www.sanofi.com/assets/dotcom/pressreleases/2024/2024-07-25-05-30-00-2918503-en.pdf [2] https://www.sanofi.com/en/our-company/our-strategy [3] https://www.sanofi.com/en/media-room/press-releases/2019/2019-12-09-21-42-41-1958232 [4] https://canvasbusinessmodel.com/blogs/competitors/sanofi-competitive-landscape [5] https://www.novaoneadvisor.com/report/us-pharmaceutical-market [7] https://www.sanofi.com/en/media-room/press-releases/2023/2023-10-27-05-30-00-2768148 [8] https://thebrandhopper.com/2024/09/02/top-competitors-of-sanofi-comprehesive-analysis-of-pharma/ [9] https://www.proclinical.com/blogs/2024-7/who-are-the-top-10-pharma-companies-in-the-world-2024 [10] https://pitchgrade.com/companies/sanofi